POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.

被引：0
|
作者：
Li, H. [1 ]
Han, T. H. [2 ]
Hunder, N. [1 ]
Jang, G. [1 ]
Zhao, B. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
[2] Stemcentrx Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-041
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [21] Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Berryman, Robert B.
    Chen, Robert
    Matous, Jeffrey V.
    Fanale, Michelle A.
    O'connor, Owen A.
    Olshefski, Randal
    Smith, Scott E.
    Huebner, Dirk
    Levine, Pamela L.
    Grove, Laurie E.
    Gopal, Ajay K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 1151 - 1153
  • [22] Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series
    Bartlett, N.
    Grove, L. E.
    Kennedy, D. A.
    Sievers, E. L.
    Forero-Torres, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] POLATUZUMAB VEDOTIN Anti-CD79b antibody-drug conjugate Treatment of hematologic malignancies
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (07) : 411 - 416
  • [24] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Lesley J. Scott
    Drugs, 2017, 77 : 435 - 445
  • [25] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Scott, Lesley J.
    DRUGS, 2017, 77 (04) : 435 - 445
  • [26] Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
    Borate, Uma
    Mehta, Amitkumar
    Reddy, Vishnu
    Tsai, Michaela
    Josephson, Neil
    Schnadig, Ian
    LEUKEMIA RESEARCH, 2016, 44 : 25 - 31
  • [27] RETREATMENT WITH BRENTUXIMAB VEDOTIN IN CD30 POSITIVE HEMATOLOGIC MALIGNANCIES: A PHASE 2 STUDY
    Forero-Torres, A.
    Brice, P.
    Chen, R.
    Fanale, M.
    Gopal, A.
    Matous, J.
    Rosenblatt, J.
    Grove, L.
    Bartlett, N.
    HAEMATOLOGICA, 2012, 97 : 85 - 86
  • [28] Therapeutic Use of Brentuximab Vedotin in CD30+Hematologic Malignancies
    Fabbri, Alberto
    Cencini, Emanuele
    Gozzetti, Alessandro
    Schiattone, Luana
    Bocchia, Monica
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (07) : 886 - 895
  • [29] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
  • [30] Brentuximab vedotin in children and adolescents with CD30-positive lymphoproliferative disorders
    Kozlov, Andrey
    Gevorgian, Asmik
    Kazantsev, Ilya
    Tolkunova, Polina
    Vigovskaya, Elena
    Eltsov, Anton
    Nikolaev, Ilya
    Morozova, Elena
    Mihailova, Natalya
    Zubarovskaya, Ludmila
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2018, 53 : 602 - 603
12345